SHORT MINI-FUTURE - ELI LILLY & CO | Real-time Boerse Frankfurt Warrants 08:01:03 2024-06-11 EDT | ||
| 12.68 EUR | -14.67% |
|
| Current month | -22.24% | ||
| 1 month | -37.54% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-06-11 | 12.68 | -14.67% |
| 24-06-10 | 14.86 | -4.19% |
| 24-06-07 | 15.51 | -8.55% |
| 24-06-06 | 16.96 | -0.18% |
| 24-06-05 | 16.99 | -2.91% |
Real-time Boerse Frankfurt Warrants
Last update June 11, 2024 at 08:01 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VD1JJP |
| ISIN | DE000VD1JJP7 |
| Date issued | 2024-03-05 |
| Strike | 1,020 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 21.44 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 27.67 € |
|---|---|
| Lowest since issue | 12.27 € |
| Spread | 0.21 € |
| Spread % | 1.63% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
865
USD
Average target price
855.2
USD
Spread / Average Target
-1.14%
- Stock Market
- Certificates
- Certificat
